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Synopsis 
Proteomic approaches to study glioma development, progression and therapy 
Astrocytoma, the tumor of astrocytic origin, accounts for about 60 % of the primary 
brain tumors.  As per World Health Organization grading system, astrocytoma is classified 
as circumscribed astrocytoma (Grade I; pilocytic astrocytoma) and diffusely infiltrating 
astrocytoma.  Grade I tumor is biologically benign and can be cured by surgical resection of 
the tumor.  The diffusely infiltrating astrocytoma is further subclassified into grade II/diffuse 
astrocytoma (DA), grade III/anaplastic astrocytoma (AA) and grade IV/glioblastoma 
(GBM).  Aggressiveness of the disease increases as the tumor progresses from lower grade 
to higher grade.  In particular, GBMs are the most malignant and aggressive human cancers.  
For a newly diagnosed GBM patient, the current treatment option is surgical resection of the 
tumor followed by radiation and temozolomide therapy. Despite the treatment is multimodal 
(surgery+radiation+temozolomide) the median survival of GBM patients remain very low at 
14.6 months.  Although numerous markers with potential utility in prognosis and treatment 
of GBMs have been reported, they are yet to be translated into clinical utility.  Our 
knowledge of understanding the complete biology of GBMs needs further comprehensive 
studies towards the identification of markers with potential utility to prognose/treat the GBM 
patients efficiently.  Therefore, with an immense need to develop new 
biomarkers/therapeutic strategies in order to improve the diagnosis, prognosis and existing 
treatment of the GBM, the current work is designed to study the following aspects on 
glioma.   
1. Identification of glioblastoma-specific serum biomarker(s) 
2. Proteomic analysis of temozolomide induced changes in glioblastoma 
 
1. Identification of glioblastoma-specific serum biomarker(s) 
Biomarker refers to a molecule whose presence reflects a particular disease state or 
severity of a disease or some other physiological condition of an organism.  In cancer, 
biomarkers have been extensively in use for disease diagnosis, prognosis and monitoring the 
treatment.  To efficiently use the biomarkers for cancer clinical management, the source of 
the biomarker must be obtained through less invasive or noninvasive method(s).  GBM is an 
aggressive intrinsic primary brain tumor.  Therefore, identification of the biomarker(s) from 
cerebrospinal fluid (CSF) will appropriately reveal the presence of a disease state in the 
brain.  But obtaining CSF from patients by lumbar puncture is a highly invasive method.  
The next appropriate source for mining the biomarker(s) appears to be serum.  Serum is 
obtained by simple non-invasive method.  Remarkably, the serum components are present in 
a highly dynamic range, it essentially reflects the normal or diseased status of an individual.  
In the present study, we used preoperative serum samples from GBM patients to 
identify biomarkers using two dimensional gel electrophoresis (2-DE) and MALDI-TOF 
mass spectrometry.  2-DE analysis of sera from normal healthy individuals (N=6) and GBM 
(N=14) patients was carried out.  ImageMaster 2D Platinum version 7.0 software was used 
for the quantitative evaluation of differentially expressed proteins.  Compared to normal 
individual serum, there were several spots found differently expressed in the glioblastoma 
sera.  However, statistical analysis revealed eight spots (spots 1 to 8) to be up-regulated and 
two spots (spots 9 and 10) down-regulated significantly (p<0.05) in glioblastoma.  The spots 
1 to 6 had a calculated molecular weight of 20.26 kDa and their pI ranged from 5.5 to 7.1.  
Based on the existing literature and human serum 2-DE databases available, these six spots 
were predicted to be haptoglobin alpha2.  Accordingly, MALDI-TOF analysis of spots 2, 3 
and 4 identified these spots as haptoglobin2 alpha (Hp2-alpha).  Subsequently, using 
haptoglobin specific antibody, we have also confirmed that these six spots are isoforms of 
Hp2-alpha.  Spot 7 and spot 8 are identified as MHC class I antigen, Angiopoietin 2 isoform 
b precursor respectively.  Spot 9 and spot 10 corresponded to Apolipoprotein A-1.  
Haptoglobin is a acute phase serum glycoprotein synthesized and secreted into blood stream 
by hepatocytes. The haptoglobin molecule is a tetrameric protein with two dimmers. The 
 subunit exists as 1 (unduplicated, 10 kDa) or 2 (duplicated, 19 kDa) but  subunits 
(undergo heavy glycosylation) are identical.  The well known function of haptoglobin is that 
it binds free hemoglobin and it prevents iron loss and renal damage.   
It was very prominent from our serum 2-DE analysis that Hp2-alpha isoforms were 
significantly elevated in the GBM patient’s sera.  Therefore, we investigated in detail the 
GBM specific up-regulation and functional consequence of haptoglobin in astrocytoma.  
Further, quantitation of serum haptoglobin on large cohort of samples by western blot 
analysis and ELISA in normal controls and patients with different grades of astrocytoma 
confirmed that haptoglobin is indeed significantly upregulated in GBM patient’s sera.  We 
then questioned whether the elevated serum haptoglobin is derived from GBM.  To address 
this possibility, we monitored the expression of haptoglobin mRNA and protein between 
normal controls and different grades of astrocytoma including GBM.  For the first time, we 
provide evidence that increased haptoglobin mRNA and protein expression is observed in 
astrocytoma and the expression level is significantly higher in GBMs (p=<0.0001 and 
<0.0001 respectively).  Using receiver operating characteristic (ROC) curve, we have also 
demonstrated that GBM-specific elevation of Hp can differentiate GBM from normals and 
lower grades of astrocytoma.  Further, we studied the putative role of haptoglobin in 
astrocytoma.  Overexpression of Hp either by stable integration of Hp cDNA or exogenous 
addition of purified Hp to immortalized astrocytes resulted in increased cell migration.  
RNAi-mediated silencing of Hp in glioma cells decreased cell migration.  Further, we 
demonstrate that both human glioma and mouse melanoma cells overexpressing Hp showed 
increased tumor growth.  
2. Proteomic analysis of temozolomide induced changes in glioblastoma 
Glioblastoma (GBM), the grade IV glioma, is highly malignant brain tumor.  GBMs 
are treated by first surgical resection of the tumor followed by radiation and temozolomide 
(TMZ) therapy.  Addition of TMZ, a DNA alkylating agent, to postoperative radiotherapy 
has been shown to improve median survival and two-year survival significantly compared 
with postoperative radiotherapy alone.   
Although, DNA repair enzyme alkyl O6-alkylguanine-DNA alkyl transferase 
(MGMT), deficient mismatch repair (MMR) system, Poly ADP-ribose polymerase (PARP) 
have been shown to determine the sensitivity of TMZ to GBM,   the mechanism of action of 
TMZ is not completely understood  yet.  Thorough understanding of the TMZ induced 
alterations in protein profiles of GBM may potentially lead to identification of new 
therapeutic strategies for treating the GBM tumors. In the present study we employed 2-
Dimensional Differential Gel Electrophoresis (2-D DIGE) approach to identify and quantify 
the TMZ induced changes in the expression of proteins in U251, a glioma derived cell line.  
We have analyzed the protein profiles of DMSO or TMZ treated U251 cells for 24 h, 48 h 
and 72 h and the biological variation analysis (BVA) was performed to identify the 
significantly differentially expressed proteins.  Temporal analysis of TMZ induced protein 
spots revealed a significant (I-ANOVA, p<=0.05) change in the expression of 95 protein 
spots in which 59 protein spots showed up-regulation and 36 protein spots showed down-
regulation.  Further, we studied in detail about four upregulated and one downregulated 
protein spots in detail.  The identities of these five proteins are confirmed by MALDI-TOF 
analysis and mascot database search as 1. glutathione synthetase (GSS), 2. breast carcinoma 
amplified sequence-1 (BCAS1), 3. interleukin-1 receptor associated kinase- 4 (IRAK4), 4. 
aspartyl t-RNA synthetase (DARS) and 5. optineurin (OPTN).  Validation of the five protein 
expression upon TMZ treatment was further confirmed by RT-qPCR and western blot 
analysis in multiple glioma cell lines  
We presumed that TMZ upregulated proteins may play role in determining sensitivity 
of glioma cells to TMZ.  To address this question, each of these four genes were 
downregulated by siRNA approach and we studied the influence of inhibition of expression 
of these proteins on TMZ sensitivity of glioma cells.   Downregulation of DARS, GSS, and 
BCAS1 did not affect the TMZ sensitivity, whereas the downregulation of IRAK4 was found 
to significantly (p<0.05) make U251 cells resistant to TMZ.  Similarly, downregulation of 
IRAK4 made U138 and LN229 glioma cells significantly resistant to TMZ (p<0.05). These 
set of experiments provided evidence that TMZ-induced IRKA4 is essential to enhance the 
glioma sensitivity to TMZ treatment.  High levels of induced IRAK4 upon TMZ treatment 
resulted in IRAK1 downregulation and inhibition of NFkB pathway. Further, we show that 
TMZ treatment in IRAK4 silenced cells failed to inhibit NFkB dependent reporter activity.  
Thus, we report here the identification of several TMZ modulated proteins and discovered an 
important novel role for IRAK4 in inhibition of TLR signaling and NFkB pathway in 
determining TMZ sensitivity of glioma cells.  
 
